Results: BAFF levels (mean, SD; pg/mL) were higher in patients receiving methotrexate (1835, 1617; $n=212$; $P=0.001$), azathioprine (1901, 1472; $n=364$; $P<0.001$) or mycophenolate mofetil/sodium (1994, 1544; $n=175$; $P<0.001$) and no immunosuppressive treatment other than the one investigated compared with patients receiving no immunosuppressive treatment (1593, 1929; $n=860$); AMA were allowed in both groups, in all comparisons. In contrast, patients on AMA displayed lower BAFF levels (1654, 1318; $n=1085$) compared with patients who did not use AMA (1942, 2408; $n=580$; $P=0.002$). In linear regression, AMA use showed a consistent and independent association with lower BAFF levels in all models, whereas use of each one of methotrexate, azathioprine and mycophenolic acid was associated with higher BAFF levels. All models were adjusted for the use of immunosuppressive agents other than the one investigated.

Conclusion: Our data imply differential effects of antimalarial agents and other immunosuppressive treatments on BAFF levels; AMA diminished while methotrexate, azathioprine and mycophenolic acid increased BAFF levels. It is worth noting that methotrexate and mycophenolic acid are not approved for the treatment of SLE. Considering the importance of BAFF in B cell homeostasis and SLE pathogenesis, exploration of the biological significance of the differential effects of different immunosuppressive agents on BAFF levels is anticipated.

Acknowledgement: The authors would like to thank GlaxoSmithKline (Uxbridge, UK) for granting access to the data from the BLISS-52 and BLISS-76 trials (ClinicalTrials.gov identifiers NCT00424476 and NCT00410384, respectively) through the Clinical Study Data Request (CSDR) consortium.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.6414

FRI0199

EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY

Luca Iaccarino¹, Francesca Saccon¹, Alessandro Mathieu², Matteo Piga², Angela Ceribelli³, Carlo Selmi³, Paolo Cardinale⁴, Armando Gabrielli⁴, Andrea Di Matteo⁵, Rossella De Angelis⁵, Paola Faggioli⁶, Antonella Laria⁷, Micaela Fredi⁸, Francesca Regola⁸, Laura Andreoli⁸, Giulia Pazzola⁹, Carlo Salvarani⁹, Francesco Puppo¹⁰, Simone Negrini¹⁰, Marcella Prete¹¹, Vito Racanelli¹¹, Elisa Gremese¹², Maria Gerosa¹³, Tania Ubiali¹³, Enrica Bozzolo¹⁴, Valentina Canti¹⁴, Fabrizio Conti¹⁵, Fulvia Ceccarelli¹⁵, Elena Bartoloni Bocci¹⁶, Roberto Gerli¹⁶, Antonio Lobasso¹⁷, Amato De Paulis¹⁷, Ginevra De Marchi¹⁸, Salvatore De Vita¹⁸, Alessandra Bortoluzzi¹⁹, Marcello Govoni¹⁹, Francesco Benvenuti¹, Margherita Zen¹, Marta Mosca²⁰, Chiara Tan²⁰, Maurizio Rossini²¹, Giovanni Orsolini²¹, Mariele Gatto¹, Salvatore Scarpato²², Enrico Brunetta²³, Aurora Zumbo²³, Gabriele Valentini²⁴, Serena Fasano²⁴, Giacomo Emmi²⁵, Maria Letizia Urban²⁵, Giacomo Tanti¹², Angela Tincani⁸, Andrea Doria¹. ¹University of Padova, Rheumatology, Department of Medicine, Padua, Italy; ²University of Cagliari, Cagliari, Italy; ³Humanitas Research Hospital, Rozzano, Italy; ⁴Polytechnic University of Marche, Ancona, Italy; ⁵Polytechnic University of Marche, Hospital Carlo Urbani, Jesi, Italy; ⁶Hospital of Legnano, Legnano (MI), Italy; ⁷Hospital of Magenta, Magenta (MI), Italy; ⁸University of Brescia, Brescia, Italy; ⁹University of Modena and Reggio Emilia, Reggio Emilia, Italy; ¹⁰University of Genova, Genova, Italy; ¹¹University of Bari, Bari, Italy; ¹²Catholic University of Sacred Heart, Rome, Italy; ¹³Hospital Gaetano Pini, University of Milano, Milano, Italy; ¹⁴Hospital San Raffaele, Milano, Italy; ¹⁵Sapienza University of Rome, Rome, Italy; ¹⁶University of Perugia, Perugia, Italy; ¹⁷Federico II University of Napoli, Napoli, Italy; ¹⁸University of Udine, Udine, Italy; ¹⁹University of Ferrara, Ferrara, Italy; ²⁰University of Pisa, Pisa, Italy; ²¹University of Verona, Verona, Italy; ²²Hospital of Scafati, Scafati (SA), Italy; ²³Humanitas Hospital, Milano, Italy; ²⁴University of Campania "Vanvitelli", Napoli, Italy; ²⁵University of Firenze, Firenze, Italy

Background: Belimumab is the unique biologic therapy available for patients with SLE.

Objectives: To investigate effectiveness and safety of belimumab in SLE patients in clinical practice.

Methods: 458 active SLE patients (ACR criteria) from 24 Italian Centers, mean±SD age 43.5±11.3 years; mean±SD disease duration 12.3±8.7 years, were treated with belimumab (10 mg/kg day 0, 14, 28 and then every 28 days), as add-on therapy.

SLEDAI-2K, anti-dsDNA, C3, C4, prednisone daily dose, DAS-28, 24H proteinuria, CLASI, PGA, Fatigue (VAS 0-10) were recorded at baseline and every 6 months. Flares were defined according to SFI. Response was evaluated according to SRI-4. Statistics were performed by pairs T-test, chi-square test and multiple logistic regression (SPSS, version 22.0).

Results: Mean±SD follow-up was 21.2±15.3 months (range 3-60). Most common features treated with belimumab were articular in 67%, mucocutaneous in 55%, and renal in 17% of cases. Improvement of clinical and serological variables, including daily prednisone dosage, was observed (Table). SRI-4 is summarized in the Figure.

At the end of follow-up 293 patients (66%) were still on belimumab. Most common cause of discontinuation were inadequate response (36%), AEs (31%), and pregnancy (8%).

Mean number of flare during belimumab treatment compared with the corresponding period before belimumab initiation decreased ($p<0.001$). SLEDAI-2K ≥ 10 was an independent predictor of response by logistic regression at month 12 and 24 ($p=0.003$ and $p=0.025$).

9,998 infusions were analyzed. 784 AEs were observed in 330 patients, SAEs were 43 in 36 patients. No severe infusion reactions were observed; 16 patients had infective SAEs, and 22 non infective SAEs.

Conclusion: We confirmed the effectiveness, the steroid sparing effect and good safety profile of belimumab in our cohort.

Disclosure of Interests: Luca Iaccarino: None declared, Francesca Saccon: None declared, Alessandro Mathieu: None declared, Matteo Piga: None declared, Angela Ceribelli: None declared, Carlo Selmi Grant/research support from: Abbvie, Janssen, MSD, Novartis, Pfizer, Consultant for: Abbvie, Alfa-Sigma, Biogen, BMS, Celgene, Eli-Lilly, GSK, Janssen, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi-Genzyme, YCB, Speakers bureau: Abbvie, Alfa-Sigma, Biogen, BMS, Celgene, Eli-Lilly, GSK, Janssen, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi-Genzyme, YCB, Paolo Cardinale: None declared, Armando Gabrielli: None declared, Andrea Di Matteo: None declared, Rossella De Angelis: None declared, Paola Faggioli: None declared, Antonella Laria: None declared, Micaela Fredi: None declared, Francesca Regola: None declared, Laura Andreoli: None declared, Giulia Pazzola: None declared, Carlo Salvarani: None declared, Francesco Puppo: None declared, Simone Negrini: None declared, Marcella Prete: None declared, Vito Racanelli: None declared, Elisa Gremese Consultant for: Abbvie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, and Pfizer, Speakers bureau: BMS, Speakers bureau: Roche, Speakers bureau: Abbvie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, and Pfizer, Maria Gerosa: None declared, Tania Ubiali: None declared, Enrica Bozzolo: None declared, Valentina Canti: None declared, Fabrizio Conti: None declared, Fulvia Ceccarelli: None declared, Elena Bartoloni Bocci: None declared, Roberto Gerli: None declared, Antonio Lobasso: None declared, Amato De Paulis: None declared, Ginevra De Marchi: None declared, Salvatore De Vita Grant/research support from: Roche, Pfizer, Abbvie, Novartis, BMS, MSD, Celgene, Janssen, Consultant for: Roche, Alessandra Bortoluzzi: None declared, Marcello Govoni Paid instructor for: Pfizer, Roche, Speakers bureau: Pfizer, Abbvie, MSD, Roche, Eli-Lilly, Celgene, Sanofi, Janssen, Francesco Benvenuti: None declared, Margherita Zen: None declared, Marta Mosca Paid instructor for: GlaxoSmithKline, Lilly, UCB, Chiara Tan: None declared, Maurizio Rossini: None declared, Giovanni Orsolini Speakers bureau: Grunenthal, Mariele Gatto: None declared, Salvatore Scarpato: None declared, Enrico Brunetta: None declared, Aurora Zumbo: None declared, Gabriele Valentini: None declared, SERENA FASANO: None declared, Giacomo Emmi: None declared, Maria Letizia Urban: None declared, Giacomo Tanti: None declared, Angela Tincani Consultant for: UCB, Pfizer, Abbvie, BMS, Sanofi, Roche, GSK, AlphaSigma, Lilly, Janssen, Celgene, Novartis, Andrea Doria: None declared

Table. Variation of clinical and serologic disease activity variables in patients with active lupus treated with belimumab

	N° pts*	Baseline	6 months	12 months	18 months	24 months	30 months	36 months	48 months	p
SLEDAI-2K	458	8.1±3.4	4.9±3.3	3.8±2.7	3.8±3.2	3.5±2.8	2.6±2.8	2.8±2.4	2.7±2.1	<0.0001
Prednisone dosage (mg/day)	458	10.5±8.1	6.7±4.6	5.3±4.7	4.5±4.8	3.8±3.7	3.5±2.9	3.4±4.3	3.4±4.5	<0.0001
DAS-28	309	3.4±1.7	2.5±1.5	2.2±1.4	1.9±1.4	1.7±1.3	1.6±1.5	1.5±1.4	1.4±1.4	<0.0001
CLASI-a	254	3.3±4.7	1.9±3.3	1.1±2.2	0.8±2.1	0.6±1.8	0.6±1.4	0.6±1.4	0.2±0.7	<0.0001
PGA (0-3)	356	1.8±0.6	1.2±0.7	0.8±0.6	0.8±0.7	0.8±0.6	0.7±0.6	0.7±0.6	0.7±0.6	<0.0001
Fatigue (VAS 0-10)	197	5.2±3.0	4.3±2.8	3.3±2.6	2.8±2.7	2.8±2.6	2.5±2.9	2.3±2.7	2.4±2.9	<0.0001
Anti-dsDNA (ELISA, KU/L)	131	230±354	144±217	118±179	107±164	99.2±162	71.5±104	74.4±145	23.0±56.2	<0.006
C3 (mg/dl)	458	50.1±38.8	57.9±41.0	61.2±41.8	59.9±43.1	62.1±41.8	59.2±43.2	64.9±42.6	73.3±45.5	<0.001
C4 (mg/dl)	458	7.7±7.7	10.1±8.5	11.2±9.3	11.2±9.1	11.9±9.3	11.0±9.3	13.8±10.1	13.6±9.7	<0.006
24-h proteinuria (g/day)	77	1.4±1.1	0.8±0.9	0.6±0.6	0.6±0.7	0.6±0.6	0.7±0.8	0.4±0.5	0.6±0.6	0.012

*Number of patients at baseline; p calculated using univariate analysis
SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index-2000; CLASI-a: Cutaneous Lupus erythematosus Area and Severity Index activity;
DAS-28: Disease activity score-28 joints; anti-dsDNA: anti-double stranded DNA ELISA; Enzyme-Linked Immunosorbent Assay; pts: patients; CLAI:
chemiluminescent immunoassay

Figure. SRI-4 after belimumab in 416 SLE patients

DOI: 10.1136/annrheumdis-2019-eular.3635

FRI0200 REVIEW OF HYDROXYCHLOROQUINE USE AND DEVELOPMENT OF A REGIONAL STRATEGY TO MINIMISE RETINAL TOXICITY

Ursula Laverty¹, Gerard Reid², Julie Silvestri², Adrian Pendleton¹. ¹Musgrave Park Hospital, Belfast, United Kingdom; ²Royal Victoria Hospital, Belfast, United Kingdom

Background: Guidelines from the Royal College of Ophthalmologists in February 2018 were developed for retinal screening for patients on hydroxychloroquine, as recent evidence suggests the risk of retinal toxicity is higher than previously reported. The prevalence of retinal toxicity in long term use appears to be 7.5% and depending on dose and duration of therapy can increase to 20-50% after 20 years of therapy. Risk is increased for patients taking more than 5mg per kg per day of hydroxychloroquine, patients on Tamoxifen and those with renal impairment. The guidelines recommend the use of a standardised referral proforma to help identify patients who are high risk.

Objectives: 1. Audit of Hydroxychloroquine use and retinal screening in the Belfast Health and Social Care Trust (BHSCT)
2. Develop a regional referral proforma and screening service for retinal toxicity

Methods: Patients who were treated with hydroxychloroquine, under the care of a consultant rheumatologist were identified on the database. A proforma was used to aid data collection and patients' electronic records were reviewed. We audited the use of hydroxychloroquine and retinal screening against current Royal College of Ophthalmology (RCO) guidelines. We designed a standardised referral proforma and regional screening strategy in conjunction with ophthalmology colleagues.

Results: There were 151 patients identified on hydroxychloroquine on the database. 40 of these patients had stopped hydroxychloroquine, 2 of which had retinal toxicity. Therefore the rate of retinal toxicity in this sample was 1.3% (2/151).

There were 111 patients who remained on hydroxychloroquine treatment with a female: male ratio of 9:1. Age range was from 22 to 84, with a mean age of 55. There were 44% of patients on hydroxychloroquine for rheumatoid arthritis, 25% had systemic lupus erythematosus, 8% had Sjogrens syndrome, 6% had pallidromic rheumatoid arthritis and 13% had other connective tissue diseases. The majority (79%) of patients were on 200mg hydroxychloroquine daily and 19% were on 400mg daily. 6% of patients had an eGFR<60. No patients were on tamoxifen. 73% of patients were on hydroxychloroquine treatment for over 5 years. Retinal screening was overdue in 64% of patients.

Conclusion: In this sample, only 1.3% of patients had evidence of retinal toxicity, although 64% of patients were overdue retinal screening. We developed a referral proforma and a regional screening strategy in line with RCO guidelines. In order to meet the RCO guidelines, we recognise the need for substantial investment in regional ophthalmology services.

REFERENCES:

[1] Royal College of Ophthalmologists. (2018) Clinical Guidelines. Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.5898

FRI0201 REAL WORLD MEDICATION USE IN INCIDENT SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS PATIENTS

Lin Xie¹, Furaha Kariburyo¹, Janvi Sah¹, Jennifer H. Lofland², Li Nan³.

¹STATinMED Research, Ann Arbor, United States of America; ²Janssen Global Commercial Strategic Organization, Horsham, United States of America; ³Janssen Research and Development, LLC, Horsham, United States of America

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that causes inflammation in connective tissues and can involve multiple organs systems. Lupus nephritis (LN) is an inflammatory kidney disease caused by SLE. There is a gap in the literature regarding the standard of care in SLE and LN patients.

Objectives: This study generated real world medication use among SLE and LN patients.

Methods: This retrospective study used data from two large administrative databases in the US: Truven Health MarketScan[®] and Optum[®] databases to identify adult patients (≥18 years of age) with ≥2 medical claims on different dates for SLE or LN diagnoses from 01JAN2013-31DEC2015. SLE was identified using the International Classification of Diseases, 9th and 10th Revision, Clinical Modification [ICD-9-CM] codes (710.0) OR ICD-10-CM (M32.10-M32.19, 32.8, 32.9). LN was captured as a subset of SLE using [ICD-9-CM: 710.0 AND (581.81 or 582.81 or 583.81); OR (ICD-10-CM:M32.14)]. The first SLE or LN diagnosis was designated as the index date. Patients were required to have continuous health plan enrollment for 1 year pre-index date (baseline period) and 1 year post-index date (follow-up period) and no prior SLE/LN diagnosis claims or belimumab medical/prescription claim during the baseline period to ensure incident patients were captured. The Truven Health MarketScan[®] and Optum[®] databases were pooled together and duplicates were identified and retained in MarketScan[®] only. Patient demographics and clinical characteristics during the baseline period were assessed. SLE treatment used during the follow-up period was evaluated and the proportion of patients that used SLE medications and average number of medical/prescription claims (#Rx) for each medication were provided.

Results: A total of 31,345 patients were identified including 30,086 SLE and 1,259 LN patients. Key results are shown in Table 1. The mean age was 52.7 years for SLE and 48.3 years for LN patients. Over 80% of the patients were female, with a mean Charlson Comorbidity Index (CCI) score of 1.1 and 1.8 for SLE and LN patients respectively. The most common comorbidities at baseline were hypertension and infections. Corticosteroids (SLE= 58.3%, #Rx=4.5; LN=66.2%, #Rx=6.5) and hydroxychloroquine (SLE=43.4%, #Rx=5.8; LN=40.7% #Rx=6.2) were the most commonly used SLE medications during 1-year follow up period. Approximately 2% of patients used biologics including belimumab (SLE=1.1%, #Rx=8.8; LN=1.4%, #Rx=8.3) and rituximab (SLE=0.9%, #Rx=4.2; LN=2.1%, #Rx=4.0).